Proprietary pipeline of next generation immunology and immuno-oncology drugs.

numab graphic numab graphic numab graphic numab graphic

Highlights of tech platform & competitive edge

Using a novel, rational process, our proprietary discovery and engineering technology yields multispecific antibody-based therapeutics with tailored pharmacokinetic properties that improve on first generation antibody therapies in terms of potency, stability, effect duration and safety. Alongside our own in-house pipeline programs we have a number of strong discovery and development partnerships with pharma and biotech.

Latest News
April 17, 2018

Numab presents preclinical data for its trispecific immuno-oncology drug ND021

Numab Therapeutics AG today presents preclinical efficacy data for…

Numab Therapeutics AG today presents preclinical efficacy data for its immuno-oncology lead product ND021 at the Annual Meeting of the American Association for Cancer Research (AACR). ND021 is a trispecific molecule that simultaneously targets PDL1 on cancer and a costimulatory receptor on T cells. The preclinical data presented today confirm the differentiating potential of ND021 in terms of efficacy and safety over PD-1/PDL1 blocking agents and their combination with antibodies targeting the costimulatory receptor. Please click on the link below to download the AACR poster presentation.
September 14, 2017

Intarcia and Numab Reach Key Milestone

Intarcia Therapeutics, Inc., and Numab Therapeutics AG today…

Intarcia Therapeutics, Inc., and Numab Therapeutics AG today announced the achievement of a key milestone in their on-going development partnership – the selection of a multi-specific antibody construct targeting autoimmune and inflammatory diseases. This delivery marks the first major milestone in the strategic relationship, established in the spring of 2015, and triggers a payment to Numab that will bring the total payments for this project to CHF 11.5 million to date.  
June 13, 2017

Numab and Kaken Pharmaceutical Co., Ltd. Enter into a Collaboration and Option Agreement

Numab Therapeutics AG (“Numab”) today announced a…

Numab Therapeutics AG ("Numab") today announced a collaboration and option agreement with Kaken Pharmaceutical Co., Ltd. ("Kaken") for the identification of a multispecific antibody candidate for development in inflammatory disease. Under the agreement, Kaken will obtain an option to conclude a license and co-development agreement after identification of lead candidate generated by Numab using its unique multispecific antibody technology platform. Kaken is to fully fund the research program.
More News
Our websites uses Google Analytics and cookies to give you the best online experience. By using our website you agree to our use of cookies in accordance with our privacy statement.